Oregon's Psilocybin Services Act in 2026: What Two Years of Legal Therapy Tells Us

When Oregon voters passed Measure 109 in November 2020, the state became the first jurisdiction in the United States to legalize supervised adult psilocybin use outside of a research setting. Service centers opened in mid-2023. Two years of operating data, license records, and field experience now let us look at what legal psilocybin therapy in Oregon actually is — separate from the headlines, the hype, and the hand-wringing.

This is a clinical landscape post for therapists, prospective clients, and anyone trying to make sense of a treatment modality that is simultaneously legal under state law, federally Schedule I, and still being built in real time. We'll cover what a Measure 109 session looks like, how licensed service centers compare to the unregulated underground, where ketamine fits in, and how a properly trained trauma-informed integration therapist becomes the single most important predictor of a good long-term outcome.

What a legal psilocybin session in Oregon actually looks like

The Oregon Psilocybin Services program, administered by the Oregon Health Authority, regulates four kinds of licensees: manufacturers, service centers, facilitators, and testing labs. Clients access psilocybin only through a three-step model:

• Preparation session. At least one hour, with a licensed facilitator, before the dosing day. The facilitator reviews medical history, current medications (especially SSRIs and lithium), intention, and integration plan.
• Administration (dosing) session. Conducted at a licensed service center. The facilitator stays with the client for the full session — typically 4 to 6 hours for a moderate dose. No phones, no leaving the center, no group dosing without specific licensing.
• Integration session. Within 72 hours of the dosing day. This is the part most non-clinical sources underestimate.

A client does not need a diagnosis or referral. There is no formal indication list. The program is regulated as a wellness service, not a medical treatment. That single regulatory decision is why the field looks the way it does — and why integration therapy has had to step into a gap the program itself does not fill.

The 6-week integration window: where the actual healing happens

Research from MAPS, the Usona Institute, and Johns Hopkins consistently shows the same pattern: the lasting therapeutic gains from a single moderate-to-high dose psilocybin session emerge during the four-to-six weeks after the experience, not during it. The session opens a window of neuroplasticity. Whether anything gets built during that window depends almost entirely on what the client does — and who they do it with — between days 3 and 42.

This is where licensed integration therapy matters. A trained integration therapist:

1. Helps the client put narrative language around a non-verbal experience.
2. Identifies which insights are real and which are state-dependent (i.e., disappeared with the substance).
3. Builds a specific behavioral practice — meditation, somatic work, journaling, relationship repairs — to anchor the changes.
4. Screens for adverse outcomes that emerge late: depersonalization, ungrounded grandiosity, suppressed grief surfacing without resources.

Without integration, a psilocybin session is a profound experience that fades. With it, the same session becomes a clinical event with durable outcomes.

Where ketamine fits in

Ketamine has been legal in Oregon for medical use since 1970. It is the only psychedelic available by prescription, off-label, in clinics statewide. The two modalities serve different niches:

• Ketamine is short-acting (40–90 minutes), highly titratable, repeatable weekly or bi-weekly, and covered partially by some commercial insurance for treatment-resistant depression. Ketamine-assisted psychotherapy (KAP) pairs the dissociative window with a therapist in the room.
• Psilocybin is long-acting (4–6 hours), legally accessible without a diagnosis, but expensive and not insurance-eligible. It is typically used as a "deep dive" — one or two sessions a year — rather than a maintenance treatment.

Several Oregon providers offer both, integrating ketamine prescription with psilocybin preparation/integration support. Maria Steiner-Renoir at MindMorph LLC in Portland and Peter H. Addy, PhD are among the better-known KAP practitioners working in Oregon. Their dual-modality practices are a useful template for anyone trying to map their own care plan.

Pricing reality, two years in

The headline figure for a Measure 109 session has settled around $2,000 to $3,500 all-in. That covers the preparation hour, the dosing session, the integration hour, the psilocybin product itself, and the service center fee. None of it is insurance-eligible. Ketamine clinics range from $400 to $800 per session, with some commercial plans reimbursing for the medical visit portion.

The cost wall is the single biggest barrier to access. Several Oregon nonprofits are building sliding-scale programs and equity scholarships for psilocybin services. Veterans and people with documented trauma histories are first in line at most of them.

How to find an Oregon integration therapist

Integration therapy is not a credential the state issues. It is a self-described modality where the floor is wildly variable. When evaluating a therapist for psilocybin or ketamine integration work, look for:

• A primary credential (LPC, LCSW, LMFT, or PsyD/PhD) issued by an Oregon board.
• Documented training in at least one trauma-resolution modality — EMDR, Somatic Experiencing, Internal Family Systems, or Hakomi.
• Comfort with non-ordinary states of consciousness — many therapists trained pre-2020 are not.
• Clear scope-of-practice language: a licensed therapist cannot administer psilocybin or refer specifically for dosing under Measure 109. They can prepare and integrate.

You can browse all Oregon providers offering psychedelic-affirming therapy on the directory, or filter further by city (most are concentrated in Portland, Eugene, Bend, and Ashland).

What two years of data tells us

By the end of 2025, Oregon had licensed roughly 30 service centers and over 350 facilitators. Adverse events reported to the state remain extremely rare — under 0.5% of sessions — and serious adverse events rarer still. Client satisfaction surveys consistently report above 80% "much improved" ratings at the six-week mark for depression, anxiety, and end-of-life distress indications.

The data is not yet long-term. The clinical research on year-out outcomes is still being collected. But Oregon's experiment has provided the first real-world dataset for supervised adult psilocybin use, and the early picture is more measured than either the boosters or the skeptics predicted: it works for many people, it is not a panacea, and the integration layer is doing more of the lifting than the substance itself.

If you are weighing this as a treatment option, the most important conversation is not with a service center — it is with a therapist who can help you decide whether psilocybin fits your particular history. Start there. Take the match quiz to find an Oregon provider with psychedelic-affirming training, or browse our full directory of psychedelic-informed therapists.